Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Phase I/II Study on 5-aminolevulinic Acid Hydrochloride (5-ALA) for Fluorescence-guided Resection of Malignant Gliomas

NCT02755142 is registered in ClinicalTrials.gov with medac GmbH as lead sponsor.

NCT NCT02755142
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02755142 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Phase I/II Study on 5-aminolevulinic Acid Hydrochloride (5-ALA) for Fluorescence-guided Resection of Malignant Gliomas
Lead sponsor
medac GmbH
Phase
Phase 1/2
Overall status
Completed
Start date
February 29, 2000
Completion date
June 30, 2001
Enrollment
21 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

brain neoplasm